Mega Pharma SRL
1.8 FTEThe score of Mega Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -13 % Total assets -14 % Headcount (avg FTE) +125 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Mega Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −3,891 € | ||||
| Equity | 158,972 € | ||||
| Cash | 91,689 € | ||||
| EBITDA | 58,606 € | ||||
| Total assets | 399,682 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 16 Jul 2026
- Year ended 31 Dec 2024filed on 17 Jun 2025
- Year ended 31 Dec 2023filed on 06 Jun 2024
- Year ended 31 Dec 2022filed on 10 Jul 2023
- Year ended 31 Dec 2021filed on 15 Jul 2022
Mega Pharma's financial analysis
- Solvency39.8%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Mega Pharma
Mega Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0840.972.479
- VAT number
- BE0840972479
- Peppol
- Registered · 0208:0840972479 · as of 29 Oct 2026
- Legal form
- SRL
- Incorporated
- 10 Nov 2011
- Registered office
- 1080 Molenbeek-Saint-Jean
- Size
- Micro · 1.8 FTE
- Latest accounts
- 2025 · filed on 16 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Mega Pharma (SRL) has been based in Molenbeek-Saint-Jean since 2011, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 3,891 € and equity of 158,972 €; its revenue is not published. With 1.8 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 39.8%, above the median of its sector (37.8%).
Companies similar to Mega Pharma
Companies in the same business, of comparable size and area, outside its group.
- Minphar Retail sale of pharmaceutical products Molenbeek-Saint-Jean · balance sheet 396,164 €
- Ureel Pharmacie Retail sale of pharmaceutical products Couvin · balance sheet 406,984 €
- Offipharma Retail sale of pharmaceutical products Froidchapelle · balance sheet 399,757 €
- Pharmacie DU LAC Retail sale of pharmaceutical products Rixensart · balance sheet 399,426 €
- ulti med Products (Belgium) Retail sale of pharmaceutical products Roeselare · balance sheet 399,335 €
- Pharmaplus Rocourt Retail sale of pharmaceutical products Liège · balance sheet 400,037 €
- Apotheek Goossens-DE Turck Retail sale of pharmaceutical products Lebbeke · balance sheet 400,153 €
- Farmalia Retail sale of pharmaceutical products Etterbeek · balance sheet 397,775 €
Frequently asked questions about Mega Pharma
What is the revenue of Mega Pharma?
Mega Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Mega Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0840972479 for Mega Pharma, if the company is VAT-registered. Its company number (CBE) is 0840.972.479.
Where is the registered office of Mega Pharma?
According to the CBE register, the registered office of Mega Pharma is in 1080 Molenbeek-Saint-Jean.
What is the equity of Mega Pharma?
At the close of the 2025 financial year, the equity of Mega Pharma amounts to 158,972 €, a solvency of 39.8% of total assets.
How many people work at Mega Pharma?
1.8 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Mega Pharma?
The register lists 1 active mandates at Mega Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Mega Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →